Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Acid-reducing Agents on Sitravatinib PK in Healthy Adults
NCT04935112Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sitravatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mirati Therapeutics. Primary endpoints: Maximum Plasma Concentration at Day 7, Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Jul 2021; status: completed.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04935112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935112.